|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||
| Current assets: | ||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||
| Inventories | ||||||||||||||||||
| Deferred costs | ||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||
| Total current assets | ||||||||||||||||||
| Non-current assets: | ||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||
| Operating lease right-of-use assets, net | ||||||||||||||||||
| Deferred costs | ||||||||||||||||||
| Other assets | ||||||||||||||||||
| Total assets | ||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||
| Current liabilities: | ||||||||||||||||||
| Accounts payable | ||||||||||||||||||
| Accrued and other current liabilities | ||||||||||||||||||
| Deferred grant | ||||||||||||||||||
| Deferred revenue | ||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||
| Total current liabilities | ||||||||||||||||||
| Non-current liabilities: | ||||||||||||||||||
| Deferred revenue | ||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||
| Deferred grant | ||||||||||||||||||
| Total liabilities | ||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||
| Preferred stock; $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding | ||||||||||||||||||
| Common stock; $0.0001 par value; 950,000,000 shares authorized; 146,080,618 and 134,536,592 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||
Loading...